Trial Profile
Early reconstitution of the peripheral immune repertoire following withdrawal of fingolimod therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Feb 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 26 Feb 2016 New trial record